Want to see PTHS full AI Analyst Report?
PTHS Stock Chart & Stats
$23.02
--
Market closed
$23.02
--
Day’s Range― - ―
52-Week Range$13.88 - $54.29
Previous CloseN/A
VolumeN/A
Average Volume (3M)30.94K
Market Cap
$89.57M
Enterprise Value$38.22M
Total Cash (Recent Filing)$32.23M
Total Debt (Recent Filing)$52.93M
Price to Earnings (P/E)―
Beta1.65
Next Earnings
Aug 24, 2026EPS Estimate
-2.82Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-40.69
Shares Outstanding3,475,645
10 Day Avg. Volume22,109
30 Day Avg. Volume30,941
Financial Highlights & Ratios
PEG Ratio-0.02
Price to Book (P/B)1.50
Price to Sales (P/S)3.47
P/FCF Ratio-2.57
Enterprise Value/Market Cap0.43
Enterprise Value/Revenue1.38
Enterprise Value/Gross Profit2.93
Enterprise Value/Ebitda-0.76
Forecast
1Y Price Target
$59.00Price Target Upside156.30% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering6
EPS Forecast (FY)-10.35
Revenue Forecast (FY)$63.68M
Bulls Say, Bears Say
Bulls Say
Revenue Scaling & Gross MarginRevenue growth from recent commercialization with a ~63% gross margin indicates attractive unit economics that can support scalable profitability as volume grows. Durable product-level margins allow the company to leverage fixed commercial costs over time and improve operating leverage as launches progress.
Commercial Launch TractionRapid prescription growth, expanding prescriber count and month-over-month momentum signal clear product-market fit and effective commercial channels. Sustained adoption reduces launch risk and means future product rollouts can leverage existing sales infrastructure for faster, lower-cost uptake.
Improved Liquidity & Balance SheetRecent debt draw and stronger working capital provide meaningful runway to fund ongoing launches and near-term investments without immediate equity dilution. Positive equity on the latest balance sheet also improves financial flexibility to execute commercialization and planned product rollouts over the coming 6–12 months.
Bears Say
Large Net LossesDeep cumulative losses reflect that operating scale has not yet absorbed high SG&A and launch costs. Persistent negative earnings will pressure returns on equity and could necessitate further financing or cost rebalancing, constraining strategic optionality until the business reaches sustained positive EBIT.
Ongoing Cash BurnSubstantial negative operating and free cash flow indicate reliance on external capital to fund growth. This structural cash burn increases refinancing risk and could force dilutive equity raises or higher-cost debt if profitability and unit economics do not improve within the next several quarters.
Rising SG&A, Interest & GTN PressureHigher commercial spend and interest costs plus anticipated gross-to-net expansion to the mid-30s compresses net revenue per unit and delays operating leverage. Structurally, this raises the sales volume threshold needed to reach breakeven and increases sensitivity to payer dynamics and pricing over time.
Pelthos Therapeutics News
PTHS FAQ
What was Pelthos Therapeutics’s price range in the past 12 months?
Pelthos Therapeutics lowest stock price was $13.88 and its highest was $54.29 in the past 12 months.
What is Pelthos Therapeutics’s market cap?
Pelthos Therapeutics’s market cap is $89.57M.
When is Pelthos Therapeutics’s upcoming earnings report date?
Pelthos Therapeutics’s upcoming earnings report date is Aug 24, 2026 which is in 50 days.
How were Pelthos Therapeutics’s earnings last quarter?
Pelthos Therapeutics released its earnings results on May 14, 2026. The company reported -$3.09 earnings per share for the quarter, beating the consensus estimate of -$3.45 by $0.36.
Is Pelthos Therapeutics overvalued?
According to Wall Street analysts Pelthos Therapeutics’s price is currently Undervalued.
Does Pelthos Therapeutics pay dividends?
Pelthos Therapeutics does not currently pay dividends.
What is Pelthos Therapeutics’s EPS estimate?
Pelthos Therapeutics’s EPS estimate is -2.82.
How many shares outstanding does Pelthos Therapeutics have?
Pelthos Therapeutics has 3,475,645 shares outstanding.
What happened to Pelthos Therapeutics’s price movement after its last earnings report?
Pelthos Therapeutics reported an EPS of -$3.09 in its last earnings report, beating expectations of -$3.45. Following the earnings report the stock price went up 6.459%.
Which hedge fund is a major shareholder of Pelthos Therapeutics?
Currently, no hedge funds are holding shares in PTHS
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Pelthos Therapeutics Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
$59.00 (156.30% Upside)
$59.00 (156.30% Upside)
Blogger Sentiment
Bullish
PTHS Sentiment 100%
Sector Average ―
Sector Average ―
Hedge Fund Trend
Decreased
By 201.0K Shares
Last Quarter.
Last Quarter.
Insider Transactions
Bought Shares
Worth $959.6K over
the Last 3 Months
the Last 3 Months
News Sentiment
Very Bullish
Bullish news 100%
Bearish news 0%
Bearish news 0%
Technicals
SMA
Positive
20 days / 200 days
Momentum
315.91%
12-Months-Change
Fundamentals
Return on Equity
-164.11%
Trailing 12-Months
Asset Growth
9999.00%
Trailing 12-Months
Company Description
Pelthos Therapeutics
Pelthos Therapeutics Inc. operates as a biopharmaceutical enterprise dedicated to developing and commercializing innovative medical treatments that address significant, unmet patient needs. Its primary offerings include ZELSUVMI, a medication specifically indicated for the treatment of molluscum contagiosum in individuals aged one year and older. Furthermore, the company leverages NITRICIL, an exclusive technological platform grounded in nitric oxide research. Established in 2002, this Durham, North Carolina-based firm was previously known as Channel Therapeutics Corporation, before rebranding to Pelthos Therapeutics Inc. in July 2025.
PTHS Earnings Call
Q1 2026
0:00 / 0:00
Earnings Call Sentiment|Positive
The call presents a largely positive commercialization story: strong prescription growth (25% QoQ), 17% revenue growth QoQ, expanding prescriber base and payer access, successful PBM engagement, and improved liquidity from a debt draw. These operational and commercial wins are tempered by ongoing unprofitable quarterly results, negative adjusted EBITDA, rising SG&A and interest costs, anticipated higher gross-to-net pressures (mid-30s), and some inventory accounting timing effects. On balance, the company shows solid early launch traction and strengthened financial flexibility while still investing heavily toward profitability and additional product launches.View all PTHS earnings summariesPTHS Stock 12 Month Forecast
Average Price Target
$59.00
▲(156.30% Upside)
Technical Analysis
Immunic
―
Fortress Biotech
―
Verrica Pharmaceuticals
―
Instil Bio
―
Tevogen Bio Holdings
―